---

Highlights of February 2021

1. Biocon Biologics to partner with International Diabetes Federation.
2. Lupin, Phil Inc partner to deliver solutions for patients on Solosec®.
3. Biocon Biologics has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to life-saving cancer biosimilars in more than 30 countries in Africa and Asia, as part of the Cancer Access Partnership (CAP).
4. Charles River jumps into cell and gene therapy manufacturing with US$875 Million Cognate buy.
5. Veracyte drops US$600 Million to acquire cancer tester Decipher Biosciences.
6. Axonics acquires Contura and its incontinence hydrogel for US$200 Million.
7. RedHill Biopharma expands partnership with Cosmo Pharmaceuticals.
8. Catalent to buy Belgian CDMO Delphi Genetics.
9. GPX Medical signs agreement with BTC Health Australia.
10. MaxiVAX and Minaris strike immunotherapy manufacturing partnership deal.

India emerges as Major contributor for Global Covid-19 Vaccination: 

1. Indian companies Bharat Biotech and Serum supply 45+ million doses to 45+ countries, and to supply many more million doses to 60+ countries. 

   Around 7 million of those doses have been donated by the Indian government.

2. WHO: "It is ONLY with India’s manufacturing capacities that the entire world can be vaccinated".
3. Pennsylvania-based Ocugen selected to market India’s Covaxin in US.
4. Serum Institute of India to send 10 million doses of Covishield to UK.
5. GAVI inks pact with Serum Institute of India, Novavax for Covid-19 vaccine supply.
6. Brazil to buy 20 million doses of Covid-19 vaccine Covaxin from Bharat Biotech.
7. Serum Institute of India to supply vaccine to Canada